-
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
-
Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%
-
Koselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas
-
OKX Ventures Joins Ethereum Climate Platform As a Launch Partner to Advance Sustainability in Web3
-
Uxin Limited Announces Successful Validation of Superstore Business Model, Significant Reduction in Losses, and Target of Achieving Overall Profitability by 2024
-
Qianhai's Intensive Digital Industrial Layout to Facilitate the Development of the GBA
-
Systecon announces new CEO and changes to the Board of Directors
-
N mobile Makes Its Disruptive Debut – Probably the best value travel & lifestyle mobile brand in Hong Kong
